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The hypocretin receptor (HcrtR) antagonist almorexant (ALM) has potent hypnotic actions
but little is known about neurocognitive performance in the presence of ALM. HcrtR
antagonists are hypothesized to induce sleep by disfacilitation of wake-promoting systems
whereas GABAA receptor modulators such as zolpidem (ZOL) induce sleep through
general inhibition of neural activity. To test the hypothesis that less functional impairment
results from HcrtR antagonist-induced sleep, we evaluated the performance of rats in the
Morris Water Maze in the presence of ALM vs. ZOL. Performance in spatial reference
memory (SRM) and spatial working memory (SWM) tasks were assessed during the dark
period after equipotent sleep-promoting doses (100mg/kg, po) following undisturbed and
sleep deprivation (SD) conditions. ALM-treated rats were indistinguishable from vehicle
(VEH)-treated rats for all SRM performance measures (distance traveled, latency to enter,
time within, and number of entries into, the target quadrant) after both the undisturbed
and 6 h SD conditions. In contrast, rats administered ZOL showed impairments in all
parameters measured compared to VEH or ALM in the undisturbed conditions. Following
SD, ZOL-treated rats also showed impairments in all measures. ALM-treated rats were
similar to VEH-treated rats for all SWM measures (velocity, time to locate the platform
and success rate at finding the platform within 60 s) after both the undisturbed and SD
conditions. In contrast, ZOL-treated rats showed impairments in velocity and in the time
to locate the platform. Importantly, ZOL rats only completed the task 23–50% of the
time while ALM and VEH rats completed the task 79–100% of the time. Thus, following
equipotent sleep-promoting doses, ZOL impaired rats in both memory tasks while ALM
rats performed at levels comparable to VEH rats. These results are consistent with the
hypothesis that less impairment results from HcrtR antagonism than from GABAA-induced
inhibition.
Keywords: hypocretins/orexins, cognitive impairment, memory impairment, hypnotics, water maze, spatial
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INTRODUCTION
Insomnia is a highly prevalent condition affecting 10–30% of the
general population; (NIH, 2005; Roth, 2007; Mai and Buysse,
2008). Sleep loss and sleep disruption can lead to a degradation
of neurocognitive performance as assessed by objective and sub-
jective measures (Wesensten et al., 1999; Belenky et al., 2003;
Lamond et al., 2007). Prescription sleep medications are often
used to treat insomnia and obtain desired amounts of sleep.
Presently, nonbenzodiazepine, positive allosteric modulators of
the GABAA receptor such as zolpidem (ZOL) are the most widely
prescribed hypnotic medications. Although known to induce
sleep, these compounds have been shown to significantly impair
psychomotor and memory functions in rodents (Huang et al.,
2010; Uslaner et al., 2013; Zanin et al., 2013), non-human pri-
mates (Makaron et al., 2013; Soto et al., 2013; Uslaner et al., 2013)
and humans (Balkin et al., 1992; Wesensten et al., 1996, 2005;
Mattila et al., 1998; Mintzer and Griffiths, 1999; Verster et al.,
2002; Storm et al., 2007; Otmani et al., 2008; Gunja, 2013). Such
impairment can be particularly troubling when there is an urgent
need for highly functional performance in the presence of drug
such as with first responders, military personnel, and caregivers.
Further, complex behaviors during the sleep period (e.g., eating,
cooking, driving, conversations, sex) have been associated with
these medications (Dolder and Nelson, 2008). Therefore, more
effective hypnotics are needed that facilitate sleep that is easily
reversible in the event of an unexpected awakening that demands
unimpaired cognitive and psychomotor performance.
Recently, antagonism of the hypocretin (Hcrt; also called
orexin) receptors has been identified as a target mechanism for
the next generation of sleep medications (Brisbare-Roch et al.,
2007; Dugovic et al., 2009; Whitman et al., 2009; Hoever et al.,
2010, 2012a,b; Coleman et al., 2012; Herring et al., 2012; Winrow
et al., 2012; Betschart et al., 2013). The Hcrt system is well known
to play an important role in the maintenance of wakefulness (de
Lecea, 2012; Inutsuka and Yamanaka, 2013; Mieda and Sakurai,
2013; Saper, 2013). Hcrt fibers project throughout the central
nervous system (CNS), with particularly dense projections and
receptor expression found in arousal centers including the locus
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coeruleus, the tuberomammilary nucleus, dorsal raphe nuclei,
laterodorsal tegmentum, pedunculopontine tegmentum, and the
basal forebrain (Peyron et al., 1998; Marcus et al., 2001). The
excitatory effects of the Hcrt peptides on these arousal centers
is hypothesized to stabilize and maintain wakefulness. Therefore,
blockade of the Hcrt system should disfacilitate these arousal
centers, creating conditions that are permissive for sleep to occur.
The current study tests the hypothesis that the dual Hcrt
receptor antagonist almorexant (ALM) produces less functional
impairment than ZOL. The rationale that underlies this hypoth-
esis is that ZOL causes a general inhibition of neural activity
whereas ALM specifically disfacilitates wake-promoting systems.
We tested this hypothesis using tests of spatial reference memory
(SRM) and spatial working memory (SWM) in the Morris Water
Maze. Although the concentrations of ALM and ZOL adminis-
tered prior to these tests were equipotent in hypnotic efficacy, the
performance of rats treated with ALM were superior to that of
rats treated with ZOL.
MATERIALS AND METHODS
ANIMALS
One hundred fifty three male Sprague Dawley rats (300 g at time
of purchase; Charles River, Wilmington, MA) were distributed
among the 12 groups as described in Table 1. All animals were
individually housed in temperature-controlled recording cham-
bers (22 ± 2◦C, 50 ± 25% relative humidity) under a 12:12
light/dark cycle with food and water available ad libitum. All
experimental procedures were approved by SRI International’s
Institutional Animal Care and Use Committee and were in accor-
dance with National Institute of Health (NIH) guidelines.
SURGICAL PROCEDURES
Rats were instrumented with sterile telemetry transmitters (F40-
EET, Data Sciences Inc., St Paul, MN) as previously described
(Morairty et al., 2008, 2012; Revel et al., 2012, 2013). Briefly,
under isoflurane anesthesia, transmitters were placed intraperi-
toneally and biopotential leads were routed subcutaneously to the
head and neck. Holes were drilled into the skull at 1.5mm ante-
rior to bregma and 1.5mm lateral to midline, and 6mm posterior
to bregma and 4mm lateral to midline on the right hemisphere.
Two biopotential leads used as EEG electrodes were inserted into
the holes and affixed to the skull with dental acrylic. Two biopo-
tential leads used as EMG electrodes were positioned bilaterally
through the nuchal muscles.
IDENTIFICATION OF SLEEP/WAKE STATES
After at least 3 weeks post-surgical recovery, EEG, and EMG were
recorded via telemetry using DQ ART 4.1 software (Data Sciences
Table 1 | The number of rats tested for each of the 12 experimental
groups.
Test No SD 6h SD
VEH ALM ZOL VEH ALM ZOL
Reference memory 14 13 17 16 16 8
Working memory 11 12 12 12 11 11
Inc., St Paul, MN). Following completion of data collection, the
EEG, and EMG recordings were scored in 10 s epochs as waking
(W), rapid eye movement sleep (REM), or non-rapid eye move-
ment sleep (NREM) by expert scorers blinded to the treatments
using NeuroScore software (Data Sciences Inc., St Paul, MN).
Sleep latency was defined as the first 60 s of continuous sleep fol-
lowing drug administration. Recordings were started at Zeitgeber
time (ZT) 12 (lights off) and continued until animals performed
the water maze tests.
SLEEP DEPRIVATION PROCEDURES
Animals were sleep deprived (SD) from ZT12-18 by progressive
manual stimulation concurrent with EEG and EMG recording.
The rats were continuously observed and, when they appeared to
attempt to sleep, progressive interventions were employed to keep
them awake: removal of cage tops, tapping on cages, placement
of brushes inside the cage, or stroking of vibrissae or fur with an
artist’s brush.
DRUGS
Almorexant (ALM; ACT-078573), was synthesized at SRI
International (Menlo Park, CA. USA) according to the
patent literature. Zolpidem (ZOL) was a gift from Actelion
Pharmaceuticals Ltd. For the SWM task, rats were dosed with
ALM (100mg/kg, p.o.), ZOL (100mg/kg, p.o.) or vehicle (VEH;
1.25% hydroxypropyl methyl cellulose, 0.1% dioctyl sodium
sulfosuccinate, and 0.25% methyl cellulose in water) at ZT18 and
left undisturbed until time to perform memory tasks (see below).
For the SRM task, most rats were also administered ALM, ZOL,
and VEH p.o. at the concentrations above. However, one cohort
of rats was administered drugs i.p. For these rats, ALM was
administered at 100mg/kg (N = 6), ZOL at 30mg/kg (N = 8)
and VEH (N = 7). ZOL is approximately 3X more potent i.p.
than p.o.(Vanover et al., 1999) while ALM is equipotent through
both routes of administration. Analysis of the sleep/wake data
confirmed the equipotent effects of both drugs through both
routes of administration at the concentrations tested.
WATER MAZE
All water maze (WM) tasks occurred in a pool 68′′ in diameter
and 25′′ in depth, containing water at 24 ± 2◦C made opaque
by the addition of non-toxic, water soluble black paint and milk
powder. Since all tests took place during the dark period, distinc-
tive spatial cues were made of small “rice” lights colored blue,
yellow, and green. Patterns of lights in distinct shapes (circle,
square, diamond, “T” shape) were clearly visible from within the
pool. Preliminary studies determined the minimum number of
lights that were needed for learning to occur. A 10 cm diameter
platform was submerged approximately 1 cm below the surface of
the water in one of 6 locations (Figure 1). The platform location
determined the orientation of the 4 quadrants used for analysis.
Both WM tasks were similar to previous reports (Wenk, 2004;
Ward et al., 2009).
TEST OF SPATIAL REFERENCE MEMORY
The acquisition phase occurred in one session consisting of 12–15
consecutive trials with a 60 s inter-trial interval. For each trial,
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FIGURE 1 | Schematic of the water maze apparatus used for both
spatial reference and spatial working memory tasks. (A) Schematic of
the platform locations. (B) Example of quadrant orientations used for
analysis used for the platform indicated in bold. Quadrant locations were
always oriented so that the platform was central within a quadrant.
rats were placed in the WM facing the wall in one of three quad-
rants that did not contain the hidden platform. The location
of the hidden platform remained constant across all trials. Rats
were given 60 s to locate the platform. If the rats did not locate
the platform within this period, they were guided to the plat-
form location. When the rats reached the platform, they were
allowed to remain on the platform for approximately 15 s before
being placed in a dry holding cage for the next 60 s. This training
sequence continued until the rats learned the task, typically 12–15
trials.
On the following day, rats were dosed with ALM, ZOL or
VEH at ZT18 and a retention probe trial was performed 90min
later in which the rats were returned to the WM but the plat-
form had been removed. A total of 40 rats were subjected to
SD for 6 h prior to drug administration, and 42 were left undis-
turbed during this period (Table 1). Rats were started in the
quadrant opposite the target quadrant and allowed to swim for
30 s. All trials were recorded by video camera and analyzed with
Ethovision XT software (Noldus, Leesburg, VA). Test measures for
the retention probe were time spent in target quadrant, latency to
target quadrant, frequency of entrance into target quadrant, and
total distance traveled. Swim speed was calculated to control for
nonspecific effects.
TEST OF SPATIAL WORKING MEMORY
The SWM task consisted of 6 pairs of trials, one for each platform
location (Figure 1A). In the first trial, a cued platform marked
with a flag was placed in one of 6 positions in the WM. Rats were
released facing the wall from one of the 3 quadrants not con-
taining the platform and were allowed 120 s to locate the cued
platform before the researcher guided the rats to the platform.
This procedure provided all rats the opportunity to learn the plat-
form location even if they did not find it on their own. After 15 s
on the platform, the rats were removed from the WM and placed
in a holding cage. The flag was then removed but the platform
remained in the same location as in the first trial. Following a
delay of 1, 5, or 10min in the holding cage, the rats were placed
back in the WM into one of the 2 quadrants that did not contain
the platform and was not the starting quadrant during the first
trial. Once the rats found the platform, they were removed after
approximately 5 s and placed back in a holding cage for 10min
before a new pair of trials with a novel platform location was
given. The order of delays was counterbalanced so that each rat
was tested twice at 1, 5, or 10min delays between the cued and
hidden platforms. All trials were recorded by video camera and
analyzed with Ethovision XT software (Noldus, Leesburg, VA).
Test measures were time to locate the platform and the swim
velocity during all tests.
STATISTICAL ANALYSIS
Statistical analyses were performed using SigmaPlot 12.3 (Systat
Software Inc., San Jose, CA). Sleep/wake data (W, NREM, and
REM time) were analyzed in 30min bins and compared between
drug groups using Two-Way mixed-model ANOVA on factors
“drug group” (between subjects) and “time” (within subjects).
SRM performance parameters (latency, duration and frequency
in target quadrant, total distance traveled) were analyzed using
a One-Way ANOVA. SWM performance measures (velocity,
time to platform, percent found) by delay time were analyzed
using Two-Way mixed-model ANOVA on factors “drug group”
(between subjects) and “time” (within subjects). Significance lev-
els were set at α = 0.05. When ANOVA indicated significance,
Bonferroni t-tests were used for post hoc analyses.
RESULTS
Drug concentrations were chosen to be equipotent at sleep pro-
motion based on our previous experience (Morairty et al., 2012).
Although ZOL produced a more rapid onset to sleep under both
SD and undisturbed conditions (No SD: ZOL = 6.6min, VEH =
32.2min, ALM= 25.4min; SD: ZOL= 5.9min, VEH= 20.0min,
ALM = 15.5min), ALM- and ZOL-treated rats slept equivalent
amounts during the last hour before the WM test (Figure 2; No
SD: ZOL = 69.4%, ALM = 62.3%, VEH = 37.6%; SD: ZOL =
69.6%, ALM = 71.5%, VEH = 52.0%).
TEST OF SPATIAL REFERENCE MEMORY
For all performance measures analyzed, rats treated with ZOL
showed significant impairments while ALM- and VEH-treated
rats were indistinguishable (Figure 3). Following ZOL, the latency
to the target zone increased (No SD: ZOL = 14.1 s, VEH = 5.7 s,
ALM = 5.8 s; SD: ZOL = 18.4 s, VEH = 4.2 s, ALM = 3.6 s) and
the duration in the target zone (No SD: ZOL = 5.5 s, VEH =
8.4 s, ALM = 7.9 s; SD: ZOL = 4.8 s, VEH = 7.7 s, ALM = 7.8 s),
frequency entering the target zone (No SD: ZOL = 1.2, VEH =
2.7, ALM = 2.5; SD: ZOL = 0.9, VEH = 2.8, ALM = 2.9) and
the distance traveled (No SD: ZOL = 472 cm, VEH = 666 cm,
ALM = 725 cm; SD: ZOL = 343 cm, VEH = 709 cm, ALM =
775 cm) all decreased compared to VEH and ALM-treated rats.
ALM-treated rats did not differ from VEH-treated rats on any
of these four measures. Performance in the SRM task was not
significantly affected by 6 h SD for any measure within any group.
Swim patterns in the WM were different for ZOL-treated rats
compared to VEH- and ALM-treated rats (Figure 4). Both VEH
and ALM rats repeatedly swam across theWMand typically swam
through the area where the hidden platform was present on the
previous day (Figure 4A). In contrast, ZOL-treated rats primarily
swam around the perimeter of the WM, a pattern typical of a rat
during its first exposure to the WM.
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FIGURE 2 | Percent time spent in W, NREM, and REM during
baseline (left panels) and during 6h SD (right panels). The vertical
line in each panel at ZT18 depicts the time of drug administration. At
the end of the recording time displayed in these panels, rats were
tested in the water maze. Note that, for the 60min prior to testing
(ZT19.5), the ALM and ZOL groups slept similar amounts. ∗, ZOL
different from VEH; +, ZOL different ALM; #, ALM different from
VEH; p < 0.05.
TEST OF SPATIAL WORKING MEMORY
ZOL-treated rats performed poorly in the SWM task compared
to either VEH- or ALM-treated rats (Figures 5, 6). ZOL-treated
rats took longer to find the platform (No SD: ZOL = 43.4–47.3 s,
VEH = 20.6–30.0 s, ALM = 22.5–30.7 s; SD: ZOL = 48.0–
55.5 s, VEH = 26.9–31.0 s, ALM = 25.6–28.2 s) and swam more
slowly (No SD: ZOL = 14.0–14.2 cm/s, VEH = 18.0–19.6 cm/s,
ALM = 18.9–20.4 cm/s; SD: ZOL = 9.9–10.9 cm/s, VEH = 15.7–
16.8 cm/s, ALM = 17.5–18.1 cm/s) than the VEH or ALM rats
(Figure 5). These measures were not affected by increasing the
delay from 1 to 5min or 10min for any of the 6 groups of
rats.
The goal for the SWM task was to locate the platform. VEH-
and ALM-treated rats found the platform the majority of the time
in both SD and undisturbed conditions (83.3–100% for VEH
and 79.2–87.5% for ALM; Figure 6). Conversely, ZOL-treated rats
failed to find the platform most of the time (22.7–50.0% suc-
cess rate). Interestingly, ZOL-treated rats also often failed to find
the cued platform during the training phase of each pair of tri-
als (Figure 7). The ZOL-treated rats in the baseline group found
the cued platform 54.4% of the time while the SD ZOL-treated
group were successful 53.8% of the time as compared to 98.6%
for ALM-treated rats in the baseline group and 100% following
SD and 100% of the time for all VEH-treated rats. A trend toward
improved performance was observed with progressive trials in the
ZOL-treated rats.
DISCUSSION
Though differing in the latency to induce sleep at the doses tested,
ALM, and ZOL were equally effective at promoting sleep during
the 90min period prior to performance testing and both com-
pounds significantly increased sleep compared to VEH. ALM-
treated rats were indistinguishable from VEH-treated rats in their
performance of both the SRM and SWM tasks. In contrast, ZOL
caused significant impairments in both tasks. Specifically, in the
SRM task, ZOL increased the latency to, the duration in, and the
frequency of entering the target zone. In the SWM task, ZOL
increased the time to find the platform, decreased the swim veloc-
ity and decreased the success rate in finding the platform. These
results support the hypothesis that dual Hcrt receptor antagonism
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FIGURE 3 | Measures of performance in the spatial reference
memory task. For all measures, ZOL-treated rats performed poorly
compared to VEH- and ALM-treated rats. For all measures, the
ALM-treated rats were indistinguishable from the VEH-treated rats.
(A) Latency to the target zone. (B) Duration in the target zone. (C)
Frequency entering the target zone. (D) Total distance traveled. For
all measures, ANOVA revealed an effect of drug condition without an
effect of SD. ∗, p < 0.05.
FIGURE 4 | Swim patterns during the spatial reference memory
probe trials following VEH (left columns), ALM (center columns)
and ZOL (right columns). (A) Examples of individual rats. The
target quadrant is highlighted in gray. (B) Traces for all rats in the
undisturbed condition. (C) Traces for all rats in the 6 h SD
condition. Note that the searching pattern for VEH and ALM are
similar while the pattern following ZOL remains primarily around
the perimeter of the maze.
effectively promotes sleep without the functional impairments
observed following GABAA receptor modulation.
An alternative explanation of the results obtained is that ZOL-
treated rats were not motivated to perform the tasks rather
than having memory/cognitive deficits. ZOL-treated rats had
decreased distance traveled during the SRM task and decreased
velocity during the SWM task, which could indicate a lack of
motivation to escape the WM. Further, the lower success rate
in finding the cued platform during the training trials for the
SWM task could be interpreted as an absence of motivation to
escape. However, ZOL rats did not simply float in the WM; they
swam continuously, primarily circling the perimeter of the WM.
As mentioned above, this swim pattern is typical of an untrained
rat during its first exposure to theWM. Although notmeasured in
this study, it is possible that the decreased distance traveled during
the SRM task and decreased velocity during the SWM task are due
to motor deficits produced by ZOL. This hypothesis is supported
by previous studies that found prominent motor effects following
ZOL administration (Depoortere et al., 1986; Steiner et al., 2011;
Milic et al., 2012).
The SD protocol in these studies was included to assess
whether moderate increases in sleep drive would exacerbate any
cognitive deficits found following ALM or ZOL administration
and also produce deficits in VEH-treated rats. While the primary
active period of nocturnal rodents such as the rat is during the
dark phase, rats still sleep approximately 30% of the time dur-
ing this period and increasing wake duration during the dark
period should create a mild sleep deficit (see Figure 2). Therefore,
a portion of our experimental protocol involved SD during the
6 h of the dark period just prior to drug administration at ZT18.
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FIGURE 5 | The time to platform and the velocity swam during
the spatial working memory task. (A) ZOL-treated rats found the
platform significantly slower than VEH- or ALM-treated rats for all
three delays following either undisturbed or SD conditions. The
ALM-treated rats were not significantly different from VEH-treated rats
for any condition. (B) ZOL-treated rats swam more slowly than either
VEH- or ALM-treated rats. ∗, different from VEH; +, different from
ALM; p < 0.05.
FIGURE 6 | Success rate in locating the platform during the test
trials in the spatial working memory task. ZOL-treated rats found the
platform significantly fewer times compared to VEH- or ALM-treated rats
for all three delays and following both the undisturbed and SD
conditions. In each trial, an individual rat either found or didn’t find the
platform; thus, there is no variation to represent as error bars in the
graphs. ∗, different from VEH; +, different from ALM; p < 0.05.
FIGURE 7 | Success rate in locating the platform during the training
trials in the spatial working memory task. The platform was cued during
these training trials by a flag. (A) The percentage of times the platform was
found across all 6 training trials. (B) The percentage of times the platform
was found trial by trial. Note that the ZOL rats tended to progressively
improve across trials. In each trial, an individual rat either found or didn’t
find the platform; thus, there is no variation to represent as error bars in the
graphs.
Although we did not find significant effects of SD vs. non-SD
within any of the 3 dosing conditions, these results are likely due
to the fact that we allowed the rats to sleep after drug adminis-
tration until water maze testing began. This undisturbed period
lasted only 60–90min but provided an opportunity for the exper-
imental subjects to recover from this mild sleep deprivation. If the
SD were continued until testing, increased memory deficits might
have been observed. Further studies are needed to determine
whether this is indeed to case.
ZOL is a widely prescribed hypnotic medication that can
be well-tolerated when taken as directed (Greenblatt and Roth,
2012). However, numerous adverse effects associated with ZOL
usage have been reported including driving impairment (Verster
et al., 2006; Gunja, 2013), effects on balance and postural tone
(Zammit et al., 2008), interference with memory consolidation
(Balkin et al., 1992; Wesensten et al., 1996, 2005; Mintzer and
Griffiths, 1999; Morgan et al., 2010) and increased incidence of
complex behaviors during sleep (Hoever et al., 2010). Some stud-
ies investigated the effects of daytime administration of ZOL and
tested psychomotor function upon arousal from naps (Wesensten
et al., 2005; Storm et al., 2007), a protocol which our experi-
ments closely mimic. In these studies, ZOL or melatonin was
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administered at either 10:00 or 13:00. Following a 1.5–2 h nap
opportunity, subjects were awakened and required to perform
a series of psychomotor and cognitive tests. Significant perfor-
mance decrements were observed following ZOL in cognitive,
vigilance and memory tasks while little to no decrements were
found followingmelatonin. The results of ZOL administration on
rat cognitive performance in the current study correlate well with
these deficits found in humans.
In contrast, the high level of performance following ALM in
both of our memory tasks suggests a high degree of safety at con-
centrations with hypnotic efficacy. Indeed, a recent study found
no performance decrements in a variant of the WM SRM task
at three-fold the concentration of ALM that we used (Dietrich
and Jenck, 2010). Furthermore, another recent study found no
effect of ALM at 300mg/kg on motor function (Steiner et al.,
2011). In humans, however, psychometric test battery assess-
ment of the effect of ALM administered in the daytime found
reductions in vigilance, alertness, and visuomotor and motor
coordination at dose concentrations of 400–1000mg (Hoever
et al., 2010, 2012a). Notably, 400mg ALM is within the therapeu-
tic dose range required to improve sleep in patients with primary
insomnia (Hoever et al., 2012b). Therefore, performance deficits
following ALM occur within the range of hypnotic efficacy
in humans. In one report, pharmacokinetic/pharmacodynamic
modeling suggests that doses of 500mg ALM and 10mg ZOL are
equivalent with respect to subjectively assessed alertness (Hoever
et al., 2010). Since we find hypnotic efficacy to be achieved at
roughly similar dose concentrations, there may be species dif-
ferences in pharmacokinetic/pharmacodynamics of ALM and/or
ZOL.While not uncommon, this makes direct translational inter-
pretations of the present data more difficult. Regardless, in both
rodents and humans, ALM appears to have a significantly bet-
ter safety profile than ZOL with regards to cognitive/memory
domains.
CONCLUSION
ALM and ZOL are effective hypnotics in multiple mammalian
species (Brisbare-Roch et al., 2007; Hoever et al., 2010, 2012a,b;
Morairty et al., 2012). They act through entirely different mech-
anisms of action, and their effects on cognition, psychomotor
vigilance and memory are in stark contrast to one another. We
found that at equipotent hypnotic concentrations, ZOL impaired
SRM and SWM but ALM did not. These results support the
hypothesis that antagonism of the Hcrt system can provide hyp-
notic efficacy without the impairments found by inducing sleep
through GABAA modulation.
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